The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death

Aug.09.2022
The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death
Synthetic marijuana is dangerous and can cause severe reactions such as seizures, heart problems, and death. It is a growing problem globally.

On August 5, 2015, a man was preparing to smoke K2, a synthetic marijuana drug, on a street in East Harlem, New York City.


Synthetic cannabis, sold under catchy names such as AK-47, K2, Spice, and Scooby Snacks, is far from being a dreamy substance. Most synthetic cannabinoids are packaged in electronic cigarettes, juices, or foods, and sold as dried plant material that has been sprayed with solvents containing laboratory-made psychoactive substances such as acetone, preservatives, or other chemicals.


According to data from the ToxIC case registry, cases of synthetic cannabis poisoning were on the rise between 2010 and 2015, with over 42,000 reported toxic exposure cases during that period. However, Tracy Klein, the assistant director of the Cannabis Policy, Research and Outreach Center at Washington State University in Vancouver, suggests that these numbers may now be decreasing in states where recreational marijuana use is allowed.


She was the lead author of a study that found that in states where recreational marijuana had been legalized between 2016 and 2019, calls to poison control center related to synthetic marijuana decreased by over one-third.


These products are in powder form, which can be sprayed or added to substances that look exactly like natural marijuana. Therefore, in party situations, I can see how someone could accidentally use it," said Klein, who is also an associate professor at the WSU College of Nursing.


However, according to the Centers for Disease Control and Prevention in the United States, people may also use synthetic cannabinoids "in an attempt to avoid positive drug screenings for employment, drug abuse treatment programs, or the criminal justice system.


A fatal issue/problem.


Over the past decade, thousands of people have been rushed to the emergency room due to marijuana use. According to the Centers for Disease Control and Prevention, some individuals have even died, including a 17-year-old boy who reportedly experienced cardiac arrest after using K2/spice marijuana once.


Experts say it is impossible to know what synthetic cannabinoids are actually present in purchased products or what other substances might be present in solvents used to soak and dry plants.


In April 2018, 153 people in Illinois fell ill and four died after using synthetic marijuana that was laced with rat poison. Later that year, in New Haven, Connecticut, K2 marijuana caused 95 people to become ill within two days. They experienced symptoms such as nausea, vomiting, lethargy, and loss of consciousness.


Klein explained that these synthetic products are officially known as "synthetic cannabinoid receptor agonists," which are different from synthetic marijuana products that have medical uses.


They do not appear in standard drug tests," she said. "The body also does not recognize them in any way that has a positive effect.


This research was published on Tuesday in the Clinical Toxicology Journal, analyzing data from the National Poison Data System between 2016 and 2019. The researchers discovered that over these three years, there were 7600 calls relating to the use of synthetic cannabinoids. Approximately 65% of calls made to poison centers concerned situations requiring medical care, with 61 fatalities reported.


A study has revealed that over half of the calls made to poison control centers (56%) were from states with restrictions on marijuana policies. According to the study, nearly one-third (38.6%) of calls were made from states that allow drug use for medical purposes, while 5.5% were from "permissive" states where recreational use is legal.


The working principle of synthetic cannabinoids.


The Centers for Disease Control and Prevention (CDC) stated that synthetic cannabinoids were first developed in the 1980s for the purpose of studying how tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, affects the brain in producing high levels.


Klein stated, "A specific synthetic marijuana was designed by a pharmaceutical company as a potential pain relief medication. People discovered that it was so potent and had so many side effects that it was not being abused.


Today, synthetic materials are mainly produced overseas and transported to the United States. In fact, according to the Centers for Disease Control, the first shipment of "goods identified as containing synthetic cannabinoids was seized at the U.S. border in 2008.


This is not just a problem in the United States. It has become an international issue", stated Klein. He pointed out that, as of February 2022, data on illegal markets listed at least 320 different types of synthetic cannabinoids being sold.


She added, "These are only those that have been reported and identified.


Klein stated that, although different from natural cannabis, synthetic compounds do indeed act on the same cannabinoid receptors as THC. However, due to the manner in which they bind to brain receptors, their potency can increase up to 100 times.


Exposure could lead to a range of neurological reactions, from mild to severe, such as agitation and depression in the central nervous system, which could even result in coma. The Centers for Disease Control and Prevention highlight other symptoms including "fatigue, irritability, confusion, dizziness, lack of coordination, inability to concentrate, stroke and seizures.


The agency stated that symptoms of mental illness include "hallucinations, delusions, psychosis, violent behavior, and suicidal thoughts." "Other physical signs and symptoms include shortness of breath, tachycardia, hypertension, severe nausea and vomiting, chest pain and heart attack, rhabdomyolysis (damaged muscles rupturing), kidney failure, and death.


The Disease Prevention and Control Center stated that there is no antidote for synthetic cannabinoid toxicity, and the long-term effects are still unknown. Treatment options include intravenous fluids, oxygen therapy, airway protection, and medication for anxiety and aggression, but these treatments are only supportive measures.


Announcement:


This article has been compiled from third-party sources and is intended solely for industry knowledge and exchange.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for industry communication and research.


Due to limitations in the level of translation ability, the translated article may not express the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and international issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles authorities searched 12 businesses and arrested 24 people during a multi-agency operation targeting illicit flavored vaping products, flavored cigarettes and counterfeit merchandise on October 22, 2026. The Los Angeles County Sheriff's Department said approximately eight tractor-trailer loads of merchandise were seized. Alleged violations involved flavored tobacco sales restrictions, tobacco licensing requirements and counterfeit trademark laws. Local, state and federal agencies participated. Authorities have not disclosed the number, brands or value of vaping products seized. Investigations remain ongoing.
Enforcement
Oct.28
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08